Supporting Information for:

Targeting small molecule drugs to T cells with antibody-directed cellpenetrating gold nanoparticles

Yu-Sang Sabrina Yang^{1,2}, Kelly D. Moynihan^{2,3}, Ahmet Bekdemir⁴, Tanmay M. Dichwalkar², Michelle M. Noh³, Nicki Watson⁵, Mariane Melo², Jessica Ingram^{5,8}, Heikyung Suh², Hidde Ploegh^{5,9}, Francesco R. Stellacci⁴, and Darrell J. Irvine^{1,2,3,6,7*}

¹Massachusetts Institute of Technology, Department of Materials Science and Engineering, Cambridge, 02139, United States. ²Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research, Cambridge, 02139, United States. ³Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, 02139, United States. ⁴École Polytechnique Fédérale de Lausanne, Institute of Materials and Interfaculty Bioengineering Institute, Lausanne, 1015, Switzerland. ⁵Whitehead Institute for Biomedical Research, Cambridge, 02142, United States. ⁶Howard Hughes Medical Institute, Chevy Chase, Maryland, 20815, United States. ⁷Ragon Institute of MGH, MIT, and Harvard, Charlestown, 02129, United States.

⁸ deceased

⁹ current address: Boston Children's Hospital

* Correspondence: djirvine@mit.edu



Figure S1. UV-vis spectrum analysis of soluble drug TGFbi (SB525334). SB525334 was dissvoled in ethanol at 20 ug/mL concentration and measured on a NanoDrop UV-vis spectrometer.



Figure S2. Size analysis of MUSOT gold nanoparticles. (a) Representative TEM micrograph of MUSOT gold nanoparticles imaged on a FEI Tecnai TEM. Scale bar = 50 nm. (b) ImageJ analysis of pooled images (total of 905 nanoparticles) revealed the average diameter of gold particles 2.4 ± 0.75 nm.



Figure S3. NMR analysis of amino ligand exchange on amph-NPs. ¹H NMR data of control MUSOT amph-NPs without amino-ligand displacement (a) and 11-amino-1-undecanethiol surface modified MUSOT amph-NPs (b). Arrow indicates peak signature of protons adjacent to the introduced amino groups on the exchanged ligand, showing ~14% of original ligands were replaced with amine ligands.



Figure S4. Anti-tumor effect of combined vaccination and TGF-βi inhibitor therapy. Shown is mean tumor size (±SEM) from groups of C57Bl/6 mice bearing B16F10 flank tumors, treated as described in Fig. 6. **, p < 0.01; ***, p < 0.001 by two-way ANOVA followed by Bonferroni's post test.